



Modulation of Anti-tumor Immunity and Tumor Microenvironment

Guest Editor:

Dr. Yu-Jen Chen

1. Chief, Department of
Biotechnology Medicine, MacKay
Memorial Hospital, Taipei,
Taiwan

2. Senior Attending Physician,
Department of Radiation

Oncology, MacKay Memorial
Hospital, Taipei, Taiwan

3. Director, Laboratory of Cancer
Therapeutics, MacKay Memorial
Hospital, Taipei, Taiwan

4. Professor, Department of
Artificial Intelligence and Medical
Application, MacKay Junior
College of Medicine, Nursing and
Management, Taipei, Taiwan

5. Professor, School of Medicine,
National Yang Ming Chiao Tung
University, Taipei, Taiwan

Deadline for manuscript
submissions:

30 September 2024

Message from the Guest Editor

Dear Colleagues,

In cancer treatment, immunotherapy has demonstrated promising clinical efficacy for the improvement of survival and quality of life. In clinical practice of cancer therapy, the combination of various treatment modalities remains an important strategy, such as the application of immunotherapy, chemotherapy, target therapy, hyperthermia and radiotherapy, etc. Therefore, research on the modulation of anti-tumor and tumor microenvironments using various therapeutic modalities is important for further augmentation of cancer treatment outcomes.

For this Special Issue, we invite you to contribute original research articles or reviews on all aspects related to the theme of "Modulation of Anti-Tumor Immunity and Tumor Microenvironment". All research regarding basic, translational and clinical studies as well as development of new therapeutic agents or drug repositioning is welcome. Relevant topics include, but are not limited to, the following:

- Anti-tumor immunity;
- Tumor microenvironment;
- Immunotherapy;
- Chemotherapy;
- Target therapy;
- Hyperthermia;
- Radiotherapy;
- Novel therapeutic agents





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)